Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 19/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27453849 | 0.94 | PTPN11 (0.43) | PTPN11MEN1KMT2AMAPK3MAPK1 | |
| SCHEMBL27453067 | 0.92 | PTPN11 (0.46) | PTPN11MAPK3MAPK1 | |
| SCHEMBL27453054 | 0.87 | PTPN11 (0.42) | PTPN11 | |
| SCHEMBL27453851 | 0.87 | PTPN11 (0.40) | PTPN11 | |
| SCHEMBL24878966 | 0.85 | PTPN11 (0.47) | PTPN11MAPK3MAPK1 | |
| SCHEMBL30110927 | 0.85 | PTPN11 (0.43) | PTPN11MAPK3MAPK1 | |
| SCHEMBL27216042 | 0.85 | PTPN11 (0.43) | PTPN11MAPK3MAPK1 | |
| SCHEMBL27216126 | 0.82 | PTPN11 (0.44) | PTPN11 | |
| SCHEMBL29281515 | 0.82 | PTPN11 (0.42) | PTPN11 | |
| SCHEMBL27453838 | 0.81 | PTPN11 (0.44) | PTPN11MAPK3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029739-B2 | SHP2 inhibitor and use thereof | PTPN1, PTPN5, PTPN2 | PTPN11 16/4885MEN1 3025/4885KMT2A 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.